EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Refractory response to entrectinib for ROS‐1 rearranged NSCLC with concurrent de novo TP53 mutation showing good response to CNS lesion, but poor duration of response: A case report

Kentaro Ito iD, Miho Nishio, Kentaro Fujiwara, Yoichi Nishii, Kengo Ushiro, Hiroki Yasui, Osamu Hataji

Thoracic Cancer · 2023

DOI: 10.1111/1759-7714.15044 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Kentaro Ito und 6 weiteren Autor:innen. Beteiligte Einrichtung: Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Entrectinib, a ROS‐1 inhibitor, has been shown to be effective for patients with ROS‐1 fused NSCLC, and has been established as the standard of care for this population. Entrectinib has been shown to achieve a better response to brain metastasis due to the characteristic of the drug having a weak interaction with P‐glycoprotein and, even in prospective studies, the intracranial response is higher. Patients have been known to acquire resistance to molecularly targeted drugs such as EGF‐TKIs or ALK‐TKIs during targeted therapy. Similarly, the mechanisms of resistance to entrectinib have been reported, but information about the effects of TP53 mutation with entrectinib are still limited. Here, we experienced a case of a patient with ROS‐1 fusion and concurrent TP53 mutation who was treated with entrectinib, resulting in a response to brain metastasis but rapid resistance to entrectinib. Our case demonstrates both the intracranial activity of entrectinib and the potential for resistance to entrectinib due to TP53 mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungBrain NeoplasmsLung NeoplasmsHumansReactive Oxygen SpeciesProspective StudiesMutationProtein Kinase InhibitorsTumor Suppressor Protein p53BenzamidesIndazoles

Stichwörter der Autor:innen

ROS-1 fusionTP53 mutationbrain metastasisentrectinib

Substanzen

Reactive Oxygen SpeciesProtein Kinase InhibitorsTumor Suppressor Protein p53entrectinibBenzamidesIndazolesTP53 protein, human

Autor:innen und Institutionen

  • Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Japan.
  • Department of Biostatistics, Yokohama City University of Medicine, Yokohama, Japan.
  • Department of Clinical Laboratory, Matsusaka Municipal Hospital, Matsusaka, Japan.

ORCID-Profile: Kentaro Ito

Zitieren

APA

Ito, K., Nishio, M., Fujiwara, K., Nishii, Y., Ushiro, K., Yasui, H., & Hataji, O. (2023). Refractory response to entrectinib for ROS‐1 rearranged NSCLC with concurrent de novo TP53 mutation showing good response to CNS lesion, but poor duration of response: A case report. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15044

Vancouver

Ito K, Nishio M, Fujiwara K, Nishii Y, Ushiro K, Yasui H, et al. Refractory response to entrectinib for ROS‐1 rearranged NSCLC with concurrent de novo TP53 mutation showing good response to CNS lesion, but poor duration of response: A case report. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15044

BibTeX
@article{Ito2023,
  author = {Ito, Kentaro and Nishio, Miho and Fujiwara, Kentaro and Nishii, Yoichi and Ushiro, Kengo and Yasui, Hiroki and Hataji, Osamu},
  title = {Refractory response to entrectinib for ROS‐1 rearranged NSCLC with concurrent de novo TP53 mutation showing good response to CNS lesion, but poor duration of response: A case report},
  journal = {Thoracic Cancer},
  year = {2023},
  doi = {10.1111/1759-7714.15044}
}
Kostenlos starten →